Bio-Rad Laboratories Inc (BIO-B)vsEdwards Lifesciences Corp (EW)
BIO-B
Bio-Rad Laboratories Inc
$365.08
0.00%
HEALTHCARE · Cap: $9.76B
EW
Edwards Lifesciences Corp
$84.37
-2.77%
HEALTHCARE · Cap: $49.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 152% more annual revenue ($6.51B vs $2.59B). EW leads profitability with a 15.4% profit margin vs 8.6%. BIO-B appears more attractively valued with a PEG of 1.21. EW earns a higher WallStSmart Score of 55/100 (C).
BIO-B
Hold47
out of 100
Grade: D+
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BIO-B.
Margin of Safety
+68.9%
Fair Value
$254.99
Current Price
$84.37
$170.62 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Areas to Watch
ROE of 2.5% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Revenue declined 0.1%
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : BIO-B
The strongest argument for BIO-B centers on Price/Book, Altman Z-Score, Debt/Equity. PEG of 1.21 suggests the stock is reasonably priced for its growth.
Bull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : BIO-B
The primary concerns for BIO-B are Return on Equity, Piotroski F-Score, P/E Ratio. A P/E of 44.5x leaves little room for execution misses.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.
Key Dynamics to Monitor
BIO-B profiles as a value stock while EW is a mature play — different risk/reward profiles.
BIO-B carries more volatility with a beta of 1.07 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 47/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bio-Rad Laboratories Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?